# Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic Syndrome

> **NCT01873703** · PHASE2 · COMPLETED · sponsor: **Helsinn Healthcare SA** · enrollment: 102 (actual)

## Conditions studied

- Myelodysplastic Syndrome

## Interventions

- **DRUG:** pracinostat
- **DRUG:** Placebo
- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT01873703
- **Lead sponsor:** Helsinn Healthcare SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2015-11
- **Final completion:** 2016-11
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2018-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01873703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01873703, "Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01873703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*